Compare SAIC & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIC | ALKS |
|---|---|---|
| Founded | 1969 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.7B |
| IPO Year | N/A | 1991 |
| Metric | SAIC | ALKS |
|---|---|---|
| Price | $114.73 | $29.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $119.44 | $42.85 |
| AVG Volume (30 Days) | 555.9K | ★ 1.7M |
| Earning Date | 12-04-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 33.14 | 2.44 |
| EPS | ★ 7.83 | 2.02 |
| Revenue | ★ $7,350,000,000.00 | $1,521,338,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.75 | $24.22 |
| P/E Ratio | ★ $14.56 | $14.70 |
| Revenue Growth | N/A | ★ 1.08 |
| 52 Week Low | $84.16 | $25.17 |
| 52 Week High | $124.11 | $36.45 |
| Indicator | SAIC | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 75.22 | 60.76 |
| Support Level | $100.00 | $27.50 |
| Resistance Level | $103.58 | $30.47 |
| Average True Range (ATR) | 2.85 | 0.75 |
| MACD | 0.97 | 0.25 |
| Stochastic Oscillator | 95.03 | 78.45 |
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.